Alpha-Beta Technology Inc, spun out of MIT, discovered, developed and commercialized novel carbohydrate based products for the prevention and treatment of infectious diseases. In January of 1999, in response to the interim results of its Phase III clinical trial for its lead product, the company liquidated its assets and closed its doors. The company was developing stage and devoting its activities towards research and development, marketing products under development, clinical trials and manufacturing. The major products of the company under development were betafectin (R), and PGG-glucan a carbohydrate product. The firm worked in conjunction and has licensing agreements with the Massachusetts Institute of Technology in Cambridge and Brigham and Women's Hospital in Boston on various research projects.
